Arteriosclerosis
Not recruitingStudy on Inclisiran for Preventing Heart Disease in High-Risk Patients
- Disease:Arteriosclerosis
- Substances:Inclisiran
Belgium- Participants:18–64 years · 65+ years
- Substances:Inclisiran
- Sponsor:Novartis Pharma AG
Rare diseases
Investigational molecules
Locations
Back to Belgium17 clinical trials in Dendermonde, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Belgium
Belgium
Belgium
Belgium
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluating new therapeutic approaches for reducing cardiovascular risks.
Cutting-edge trials examining novel compounds for improving cardiovascular outcomes.
Studies investigating treatments for atrial fibrillation and stroke prevention. Research comparing new anticoagulation therapies with established treatments for preventing systemic embolism.
Advanced clinical research focusing on improving outcomes in cardiac rhythm management.
Research targeting rare cardiac conditions including transthyretin amyloidosis with cardiomyopathy. Evaluation of innovative treatments for specific cardiac pathologies.
Focused studies on improving survival rates and quality of life in specialized cardiac conditions.
Clinical trials examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Studies evaluating new therapeutic options for stroke prevention and management.
Development of advanced treatments for better stroke outcomes.
Studies investigating the role of acetylsalicylic acid in improving survival rates for colon cancer patients. Research focused on preventing cancer recurrence after surgical intervention.
Innovative approaches in cancer survival improvement strategies.
Tell us about your condition – we search every trial in Europe and connect you with the right site.